On September 2, 2025 Abkyu, Inc., a biotechnology company specializing in single-domain antibody (VHH) discovery, reported a strategic discovery partnership with Jeevan Therapeutics, a biotechnology company founded by experienced industry leaders in biologics and small molecule development (Press release, Jeevan Therapeutics, SEP 2, 2025, View Source [SID1234656393]). The collaboration, valued at up to $200 million, will leverage Abkyu’s proprietary VHH discovery platform to accelerate the development of next-generation therapeutics aimed at addressing complex disease biology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Jeevan Therapeutics will gain dedicated access to Abkyu’s discovery platform and downstream engineering expertise to develop VHH candidates against its primary drug target. In return, Abkyu will receive an upfront payment and is eligible for additional regulatory and clinical milestone payments and commercial royalties.

"We couldn’t be more excited to partner with Jeevan Therapeutics," said Travis LeGuyader, co-founder of Abkyu. "Our platform was built specifically to enable the kind of therapeutics their team is developing and is designed to significantly increase the chances of success by identifying molecules that precisely match the target product profiles (TPPs) they are pursuing. Partnering with Jeevan not only allows us to leverage our platform to help address a largely underserved patient population but also to align with a team that shares our vision for the potential of VHHs and the breadth of their therapeutic applications."

"Partnering with Abkyu represents a pivotal step forward for Jeevan as we advance our mission to deliver transformative therapies for patients with significant unmet needs," said Terrence West, CEO and Co-Founder of Jeevan Therapeutics. "Abkyu’s cutting-edge VHH discovery platform, combined with our expertise in precision biologics and drug development, positions us to accelerate the creation of next-generation therapies designed to improve long-term patient outcomes."

This partnership reflects a shared vision to accelerate the development of next-generation biologics and expand treatment options for patients with significant unmet needs. By uniting Abkyu’s powerful VHH discovery platform with Jeevan’s innovative therapeutic strategy, the collaboration seeks to deliver therapies that set new standards for efficacy and long-term patient benefit.

On September 2, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 (Press release, Aligos Therapeutics, SEP 2, 2025, View Source [SID1234655629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.

On September 2, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious neurological and ophthalmic conditions, reported that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference, on September 8, 2025, at 11:30am ET and at Baird’s 2025 Global Healthcare Conference, on September 9, 2025 at 12:50pm ET (Press release, Lineage Cell Therapeutics, SEP 2, 2025, View Source [SID1234655646]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in scheduling an in-person meeting with the Lineage management team should contact their H.C. Wainwright or Robert W. Baird & Co. representatives directly. A replay of Lineage’s presentation from the H.C. Wainwright 27th Annual Global Investment Conference will be available on the Events and Presentations section of Lineage’s website, following the conclusion of the conference.

On September 2, 2025 BostonGene, a leader in AI-powered solutions for drug discovery and development, reported the publication of a collaborative study*, "AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma," in Cell Reports Medicine (Press release, BostonGene, SEP 2, 2025, View Source [SID1234655677]). The study introduced the largest harmonized transcriptomic and clinical dataset in kidney cancer and presents a model of how advanced multimodal AI solutions can identify previously unknown determinants of response to combinations of immunotherapy and VEGF inhibitors in solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While immune checkpoint inhibitors (ICIs) and VEGF inhibitor specific tyrosine kinase inhibitors (TKIs) have transformed care, treatment for metastatic clear cell renal cell carcinoma (ccRCC) remains challenged by variable responses, frequent progression and therapy-related toxicities and a lack of guidance on when to apply combination versus single agent therapy. Previous predictive models showed promise, but lacked reproducibility and biological interpretability across independent cohorts.

Leveraging more than 3,600 patient samples and harmonized clinical data, researchers developed a multimodal foundation model trained on extensive real-world datasets that integrates genomics, transcriptomics and tumor microenvironment (TME) profiling. The digital twin-like model generated representations of patient biology. It uncovered five novel Harmonized Immune Tumor Microenvironment (HiTME) subtypes — distinct categories of ccRCC defined by unique immune infiltration patterns, genomic alterations and prognostic outcomes. Importantly, these subtypes were validated with spatial proteomics, ensuring predictions mapped directly to tumor biology rather than functioning as a "black box."

Using the HiTME subtypes, researchers generated clinically interpretable responder scores that correlated with survival outcomes for both ICIs and TKIs across independent cohorts. This led to a decision-tree tool that stratified patients into ICI-preferred, TKI-preferred or non-responder categories, establishing a data-driven methodology to stratify patients by underlying immune and tumor biology, enabling new insights for drug development and clinical research. The framework also revealed a therapy-resistant subgroup characterized by immune-desert phenotypes and angiogenic signaling–highlighting urgent unmet needs and new therapeutic avenues.

"This study demonstrates how multimodal foundation models can reshape oncology," said Nathan Fowler MD, Chief Medical Officer at BostonGene "By grounding predictions in tumor biology rather than opaque algorithms, we enable clinicians to understand why patients may or may not respond to treatment — making AI both clinically actionable and scientifically trustworthy."

On September 2, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 (Press release, Aligos Therapeutics, SEP 2, 2025, View Source [SID1234655629]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the on demand presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.